Introduction Protein-protein interactions
Proper cellular behavior is governedb yal arge map of interactions between various protein partners, the so-calledi nteractome. [1] Researchi nto protein-protein interactions (PPIs) has emerged as an important and challengingf ield in chemical biologya nd medicinal chemistry. [2] New and classicals creening approaches in combinationw ith medicinal chemistry have broughtmore than 12 small-molecule PPI modulators into clinical development, andi ti se xpected that the market for this class of compounds will reach 600 million EUR in the next five years. [3] However, the designo fm olecules that interfere with these interactions is hindered by the size and topologyo fp rotein-protein interfaces.T he surface of many proteins has evolved to interact either with other proteins or with small molecules. The contact area in ap rotein-protein interface is considerably larger (1500-3000
2 )t han the average contact surfacei nt he interaction between proteins and smallm olecules (300-1000 2 ). [4] In addition, protein-protein interfaces tend to be flat and often lack the grooves or cavities [4] normally present in protein surfaces involved in the binding of small molecules. These considerations led to the concept of protein "druggability" coined by Hopkins and Groom. [5] Despite the large size of protein-protein interfaces, early studies revealed that not all interfacial residues contributee qually to complex stability. [6] As mall subset of critical residues,c alled hot spots, [7] are responsible for al arge fraction of the binding free energy. It has also been pointed out that large PPIs are often dominated by hot segments, which are continuous peptides tretches
The modulation of protein-protein interactions (PPIs) is emerging as ah ighly promising tool to fight diseases. However, whereas an increasing number of compounds are able to disrupt peptide-mediated PPIs efficiently,t he inhibition of domain-domain PPIs appears to be much more challenging. Herein, we report our results related to the interaction between vascular endothelial growth factor (VEGF) and its receptor (VEGFR). The VEGF-VEGFR interaction is at ypical domaindomain PPI that is highly relevant fort he treatment of cancer and some retinopathies. Our final goalw as to identify ligands able to bind VEGF at the region used by the growth factor to interactw ith its receptor.W eu ndertooka ne xtensive study, combining av ariety of experimental approaches, including NMR-spectroscopy-based screening of small organic fragments, peptidel ibraries, and medicinal plant extracts. The key feature of the successful ligands that emerged from this study was their capacity to expose hydrophobic functional groups able to interactw ith the hydrophobic hot spots at the interacting VEGF surfacepatch. that contribute the most to the bindingi nteraction energy. [8] These observations have important implicationsf or the development of small-molecule inhibitors of PPIs. These interactions have been traditionally considered as targets with low druggability potential. However,t argeting hot spots or predominant hot segments makesi tp otentially feasible to disrupt PPIs by means of small-or medium-sized molecules.
VEGF-VEGFR:atherapeutically relevant protein-protein interaction system
Vasculare ndothelial growth factor (VEGF or VEGF-A) is probably the mosti mportant soluble factor involved in tumora ngiogenesis. [9, 10] VEGF belongs to the PDFG supergenef amily, which in mammals also includes VEGF-B, -C, -D,a nd -E, with which the former sharesav aryingd egree of homology.V EGF is ag lycoprotein expressedi nv ariouss pliced isoformsr anging from 121 to 206 residues in length, and its 165-amino acid isoform is the most abundant. All these isoforms share ac ommon homodimericN -terminal receptor binding domain that has the ability to bind three tyrosine kinase receptors, namely,V EGFR-1( also known as Flt-1), VEGFR-2, and VEGFR-3.
[11] VEGF monomers are arranged in an antiparallel manner and are covalently linked by two symmetrical intermonomerd isulfide bridges between Cys51 and Cys60. The monomer structure is characterized by af our-stranded central b sheet (i.e.,s trands b1, b3, b5, and b6) that is stabilized by ac ystine knot motif formed by three intramolecular disulfide bonds (i.e.,C ys26ÀCys68, Cys57À Cys102, and Cys61ÀCys104) at one end and by as mallh ydrophobic core at the opposite end. The structure also contains three additional short b strands( i.e., b2, b4, and b7) and two a-helicals egments( i.e., a1a nd a2). [12] Twos ymmetric receptor binding surfaces at the poles of the VEGF homodimer have been identified by mutationala nd structural studies. [13] The crystal structure of the VEGF-VEGFR-1 complex [14] revealed that no major conformational changes occur on VEGF upon receptor binding andt hat the intermolecular interaction is mediated mainly by hydrophobic contacts. Both X-ray [12] and NMR spectroscopys tudies [15] suggestt hat the receptor binding region of VEGF has intrinsic conformational flexibility.S uch flexibility may have important functional implications that allow the protein to interactwith multiple receptors.
VEGF is overexpressed in most tumors and has ad irect effect on sprouting angiogenesis. [16] It also acts as as urvival factor by enhancing the expression of anti-apoptotic factors such as Bcl-2. [17] In general,V EGF induces receptor dimerization and activation of its kinase activity through autophosphorylation, which triggersaseries of intracellulars ignaling pathways; it also sets off severalp rocesses common to other growth factors, namely,cell migration, survival, and proliferation. [18] VEGF is particularly interesting as at herapeutic target because it acts directly on genetically stable endothelial cells rather than on tumor cells. Therefore, drugs that target VEGF are less pronet oi nduce mutation selection on tumor cells and ultimately confer them with drug resistance. [19] VEGF inhibition suppresses tumor growth in animal models. [20] VEGF has also been identified as ak ey target to mitigate the effects of both wet age-related macular degeneration (AMD)a nd diabetes maculare dema (DME),w hicha re vision-limiting complications of aging and diabetes, respectively.D ME affects nearly 30 %o f diabetesp atients,w hereas AMD is the main cause of permanent vision loss in the elderly. [21] High concentrations of VEGF have been correlated with chronic retinal microvascular damage. To date, 11 drugst hat disrupt VEGF signaling have been approved for the treatment of several cancert ypes [22] and diseases related to macular degeneration. [23] Of these, seven (i.e.,s unitinib, [24, 25] sorafenib, [26, 27] pazopanib, [28, 29] vandetabnib, [30] axitinib, [31] regorafenib, [32] and cabozantinib [33] )a re small molecules that inhibit the intracellular tyrosine kinase activity of the receptor.O ft he remaining four drugs,t wo are monoclonal antibodies targeting either circulating VEGF (i.e., bevacizumab [34] )o rt he soluble extracellular fraction of the VEGF receptor (i.e.,r amucirumab [35, 36] ). In addition, ac himeric fusion protein (i.e.,a flibercept [37] )a nd an aptamer (i.e.,p egaptanib [38] )h ave been described to block VEGF. Recently,as mall molecule interacting with the VEGFR-1 D2 domain and preventing VEGF bindingw as reported. [39] In the present study,w ee xplored the capacity of smallm olecules to directly target the VEGF protein. The results of screening peptide and fragment-based libraries and plant extractsa re discussed.
Results
We tackledt he discovery of VEGF ligands by using several experimental approaches, including fragment screening, design and evaluation of linear and cyclic peptidel ibraries, and screening of plant extracts used in traditional Chinesem edicine. We focusedo ur methodology on the use of NMR spectroscopy,i ncluding the implementation of ah ighly efficient chemicals hift perturbation (CSP) methodb ased on methyl- 13 CMethionine selectivel abeling of VEGF.C omputational chemistry was used to assist the screening process and was used to facilitateinterpretationoft he results.
Selectivemethyl-

13
C-methionine-labeled VEGF for binding studies VEGF 11À109 (from now on VEGF), ac onstruct comprising residues 11-109 and containing the structured homodimericN-terminal receptor binding domain, was chosen because its expression procedure and its backbone assignment have already been described. [15] By using 1 H- 15 NH SQC NMR spectroscopy experiments, au niformly 15 N-labeled VEGF sample was used to confirm both its fold integrity and its capacity to interactw ith v107, ap eptidet hat binds with high affinity to the same regiono fV EGF that interacts with the VEGF receptor. [40] In the presence of v107, considerable changes in moret han 50 [41] and WaterLOGSY experiments, [42] T 2 -relaxation edited experiments, [43] and 19 FNMR spectroscopy. [44] However,t hese techniquesa lso have some limitations. In particular, for complex mixtures, such as plant extracts,d econvolution of the contribution of each individual component may be challenging. In addition, NMR spectroscopy methods based on the existence of af ast equilibrium between the bound andf ree ligands may not be able to detect strong binders. Therefore, we focused our efforts on designing ac ost-effective and time-efficient screening method that preserved the relevant mapping information. One wayt oa chieve this goal is the NMR observation of specifically labeled sidechain resonances of the target protein. This approach has the potentialt oi mprove both the sensitivity and spectral resolution of the NMR spectra. Moreover,a ss ide chains are less prone to long-range CSP effects, they may be more reliable than amide signals for the extraction of structural information.
The mode of interaction of VEGF with its receptors [14, 45] and severalp eptides [40, 46, 47] was extensively studied and structurally characterized. Of the five VEGF methionine residues, two (i.e., Met18 and Met81) participatei nt he interaction with either v107 or VEGFR-1 and become deeply buried in the complex interface. Therefore, incorporationo fs electively labeled methionine residues may enable the study of the intermolecular interactions of VEGF.T he presence of three methionine residues (i.e.,Met55, Met78, and Met94) outside the interface could provide extra information about the specificity of the interaction. The use of methioninea salabeling probe presents severala dditional advantages.I ncorporation of commerciallya vailable methyl-13 C-methionine into proteins can be easily accomplished by using methioninea uxotrophic E. coli strains. These strains are widely used in protein crystallographyt os olve the phase problem by using selenomethionine. [48] The labeling procedure is cost effective as only 80 mg of methyl-13 C-methionine (~300 E g À1 )p er liter of growth media is required. Most importantly, 13 C-labeled methyl groups show high sensitivity and favorable NMR relaxation properties. [49] The combined use of methionine isotopic labeling and NMR spectroscopy detection was previously described for ac arboxymethylated enzyme [50] and for in-cell NMR spectroscopy experiments. [51] Methyl-13 C-Met-labeled VEGF was obtained following the procedure described for uniformly 15 N-labeled VEGF, [52] except that the methionine auxotrophic E. coli B834 strain was used and the minimal medium for cell growth was supplemented with methyl-13 C-Methionine. The protein yield was not greatly affected by the use of auxotrophicc ells. Selectively methyl- 13 CMet-labeled VEGF displayed the expectedf ive correlation signals in the 1 H- 13 CH SQC NMR spectra ( Figure 1 ). The addition of v107 revealed that, as expected, the mosta ffected signals corresponded to methyl groups in Met18 and Met81.T he largest change was detected on Met18, probablya saresult of considerable contacts with Trp13 of v107 and the effect of its aromaticr ing currents.T he remaining methionine residues (i.e.,M et55, Met78, and Met94) were virtually unaffected by v107.
Evaluation of linear and cyclic oligopeptides
Oligopeptidesc an be considered privileged structures to modulate PPIs given that their chemical structure is identical to that involved in PPI interfaces. In addition, they are modular compounds, they cover al arge chemical space,a nd they can be easily synthesized.
We designed two groupso fa ll-d dipeptides. The first one was inspired in the retro-enantioversion [53] of peptidev 107, which was dissected into as eries of 20 dipeptides ( Table 1) . The second group of 6p eptides wasc omposed by combining ar epresentative set of amino acids, including Ala, Ile, Trp, Glu, Arg, and Ser (Table 1) .
All-d dipeptides were evaluated against VEGF by STD and WaterLOGSYexperiments. However,a fter extensive exploration of as eries of experimental parameters (e.g.,p rotein and ligand concentration, number of scans, saturation time, and saturation frequency), none of the all-d dipeptides seemed to bind VEGF. C-Met-labeled VEGF sample. Evidence of binding was only observed for the Trp-Glu-containingc yclic hexapeptide (Figure 2 ). In the presence of the Trp-Glu-containing cyclic hexapeptide, selective CSPs were induced in the two VEGF methionine residues (i.e.,M et18 and Met81) located in the receptori nterface, whereas the remaining methionine residues were almostu naffected. Titration experimentsi ndicatedt hat the Trp-Glu-containing cyclic hexapeptideb inds VEGF in the low-millimolar range.
These promising resultsencouraged us to evaluateamassive library of cyclic peptides to explore ab roader range of sequences and cycle sizes. For this purpose, we used ar ecently developed in vitro selection technology referred to as RaPID (random nonstandard peptidei ntegrated discovery) system. [54] The RaPID system combines an RNA display method with flexible in vitro translation(FIT) technology used for the production of nonstandard peptides. [55, 56] With this methodology,s pecific sequences of nonstandard peptidesc an be ribosomally expressed according to their mRNAt emplates. [57] The FIT system has been applied to the synthesis of aw ide variety of XaatRNAs, for which Xaa represents proteinogenic and nonproteinogenica mino acids [58] [59] [60] [61] [62] (see the Supporting Information). The selection on the mRNA display technology was performed with am RNA library encoding for peptides from 5t o1 5a mino acids with randoms equences ands howed enrichment of specific motifs (see the Supporting Information). The 10 macrocyclic peptides with the highest score were synthesized. Five of them were prepared as fluorescein-labeled compounds (Table 2) . Macrocyclic peptidesw ere synthesized by using Fmoc/tBu peptide chemistry on as olid support. They were obtained in low yields (< 1%), which could be attributed to the high frequency of bulky 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf)-protected arginine and b-branched amino acids and to the presence of multiple conformations of the final macrocycle.
The VEGF binding ability of unlabeledm acrocyclic peptides (i.e.,p eptides 1-5,T able 2) was evaluated by fluorescencep olarization in ac ompetitive assayw ith ap reviously described Nterm. Dipeptide [a,b] HAc-
[a] Amide as Cterminus.
[b] Xaa = Ala, Ile, Ser,G lu, Arg, and Trp. www.chemmedchem.org fluorescent probe. [63] None of the tested peptides induced observable changes in the polarization signalo ft he probe (results not shown). These resultss uggest that either they do not bind to the protein interfacew ith sufficient affinity to displace the tracer or they bind to other regions of the protein. Alternatively,f luorescent-labeled peptides (i.e.,p eptides 6-10,T able 2) were assayed directly with VEGF to assess their interaction ability.H owever,n oneo ft he peptides showeda ny significant binding to VEGF.
Screening of fragment-based libraries
Af ragment-based ligand discovery( FBLD) approachw as selected, because it provides ah ighly effective way of exploring chemicals pace. [64] [65] [66] Fragment assembly allowsa ccess to very large numberso fp otential fragment combinations. Although initial fragment hits are typically weak binders, two or more fragments can be covalently linked to yield medium-sized binderswith higher affinity.
We used ac hemical library that was designed by following ar ational selection procedure from ac atalog of more than 1.2 million compounds from several international vendors (e.g., Maybridge, Asinex and Enamine, Life Chemicals, Vitasmlab, and Specs). The design workflow is shown in Figure 3 . All compounds in the library had commercial analoguest op erform what Hubbard and collaboratorsreferred to as a" structurea nd activity relationship (SAR) by catalog". [67] This concepti mplies that analogues from the originalc luster can be ordered for each active fragment, which thus generatesS AR data in as traightforward manner. Af inal library containing approximately 500 fragments, each one representing al arge cluster, was built.
To speed up the fragment screening, ap reviouslyd escribed computational approach [68] was used to group compounds into cocktails that have minimized NMR signal overlap.T his approach translates the NMR spectra of each compound into ac omputer-readablef ormat (fingerprint) and then minimizes the globals ignal overlap by aS A( Monte-Carlo-Metropolis) algorithm. Using this algorithm, 81 five-fragmentm ixtures, containingatotal of 402 compounds,w erep repared. Thef ragment mixtures showed an average signal overlap of only 2%. Once assayed against VEGF by STD experiments, ag roup of potentialV EGF binders (27 %) was selected from the initial library.T hen, we explored whether they were interacting at the expected site by using ac ompetition STD experiment in the presence of v107. However,n oe videnceo fd isplacementb y v107 was observed for any of the fragments tested.
Alternatively, ar educed set of 100 compounds was tested in a 19 FNMR spectroscopy competition assay based on the displacemento fafluorinated "spy molecule" from the binding site of VEGF.F or this purpose, af luorinated v107-based peptide was designed and synthesized (see the Supporting Information). Twoc andidates seemed to partially competew ith the spy peptidei nt he 19 FNMR spectroscopy assay.U nfortunately, binding of these fragments to VEGF could not be validated by protein-observed NMR spectroscopy techniques and they were discarded. 19 FNMR spectroscopy was also used to directly screen ap reviously described collection (FFCNIOl ibrary) of approximately 380 fluorinated compounds [69] against VEGF.T hey were grouped in eight-compound mixtures with non-overlapping 19 FNMR signals. We detectedf our low-affinity binders from the FFCNIO library in the primary cocktail screening (see the Supporting Information). However,n one of these compounds behaved as an efficient and selective VEGF binder if studied in isolation.
Several computational approaches,i ncluding molecular docking and induced-fit docking calculations, were used to further evaluate the fragment-based approach. The SiteMap module of the Schrçdinger Suite [70] identified four potentially druggable areaso nt he protein surface (i.e.,s ites 1, 2, 3, and 4 in Figure4a) . Remarkably,the protein region involved in receptor and v107 binding (i.e.,s ite 5, Figure 4a )w as not among the most "druggable"regionsofVEGF.Next, by means of docking calculations by using XP Glide (Schrçdinger), [70] we examined the previously mentioned fragment-based library of approximately 500 compounds( M r :1 50-300 Da). XP Glide docking also confirmedt he SiteMapr esults and showedb etter binding optionsf or sites 1a nd 2o utside the receptor binding site (Figure 4b ). Finally,t he search for potential transient surface clefts by ap rotocol for induced-fit docking with Protein Energy Landscape Exploration (PELE) [71] did not predict any well-formed cleft in the receptor recognition region of VEGF. Ta ken together,t hese in silico studies suggested that the most probableb inding regions of small fragments fallo utside the receptor binding site of VEGF. Ac onsiderable number of drugs that are currently used in cancer therapy are naturalp roductso rt heir derivatives. [72, 73] In this regard, traditional medicinal plants offer enormous potential in the search for new potentiald rugs.C ancer is among the conditions treated by traditional herbalm edicine. Interestingly, some of the antitumoral plants or compounds used in traditional medicine operate through an antiangiogenic mechanism, modulating one or various targetsi nvolved in vessel formation. From the literature on traditional Chinese medicine, [74] we selected as mall subset of 50 plants for their high recurrence in medical prescriptions. Dried plant material was extracted with water by means of aS oxhlet apparatus. Given that VEGF only contains five methionine residues, protein-detected 13 C-filtered- 13 C-decoupled 1 HNMR spectroscopy was used to detect potentialV EGF binders. The spectra were obtained with ao ne-dimensionalv ersion of the 1 H- 13 CH SQC pulse sequence, and they provided enough resolution to individuallyr esolve the resonanceso ft he VEGF methionine residues in at ime-efficient manner.I dentical experiments werea cquired for free VEGF and for VEGF after the addition of mixtures of three different plant extracts. Twoe xtract mixtures induced spectral changes in VEGF.N ext, individuale xtracts from the positive mixtures were added to the protein. Small,y et dose-dependent, minor shifts were observed for Met18 and Met81 in the presence of extracts from Medulla Junci and Radix scutellariae ( Figure 5) . In both cases, the shifts observed were typical of weak bindersinafast exchange regime.
The chromatographic profiles of these extracts are showni n Figure5.W ep ursued the isolation andc haracterization of the active compound(s)i nvolved in VEGF binding. Using ac ombination of mass spectrometry andh omonuclear (COSY and NOESY) and heteronuclear ( 1 H- 13 CH SQC and HMBC) NMR spectroscopy techniques, the major component of the R. scutellariae extract was identified as baicalin [75] (Figure 6 ). We then confirmed that isolated baicalin wasa ble to bind VEGF (Figures 5a nd 6) .
STD experiments were performed to identify the binding epitope of baicalin (Figure 6 ). Relative quantification of transferred saturation indicated that the most buried part of the molecule was the phenyl group, whereas the least saturated and consequently the most exposed part was the more hydrophilic glucuronic moiety.F inally,aSTD competition assay with peptidev107 was performed. Increasing amounts of v107 were added to the baicalin-VEGF sample and subsequent STD experiments were recorded. As shown in Figure 6 , these experiments revealed as tepwise reduction in the baicalin STD signals, which became undetectable in the presence of 100 mm peptidev 107, which therebyi ndicated that baicalin and v107 competefor the same binding site.
The interaction of baicalin with VEGF was furtherc haracterized by 15 NH SQC shifts, respectively (see the SupportingI nformation). Although baicalin is aw eak binder,i tp rovides ar easonable starting point to explore other structurally related, commerciallya vailable compounds.
As mall set of severalb aicalin-related compounds were chosen (Figure 7a ). These molecules conserve the flavones caffold and show minor variations in the number and positiono f severala romatic hydroxy groups.O ft hese molecules, the glycosylated flavoneq uercetin-3-b-glucoside was the only one that induced methionine perturbations on the www.chemmedchem.org similarities, most of the changes produced by baicalinw ere concentrated around residues 86-93, located at b-strands 5 and 6a nd their interconnecting loop. Conversely,q uercetin-3-b-glucoside-specific perturbationsw ere mainly located on the opposite site of VEGF,a roundP he36 and the loop connecting to the second b strand.T hese observations suggest that baicalin and quercetin-3-b-glucoside targeto verlapping but slightly differents ites on VEGF owing to their distinct binding orientations. Given that the two VEGF ligands share ac ommonf lavone scaffold andd iffer mainly in the type and location of the glycosidicm oiety and to al esser extenti nt he positiono fv arious hydroxy groups, it is reasonable to place the common scaffold on the locus of Phe47, the region equallya ffected by these two flavonoid analogues. This model is in agreement with the experimental STD data, which suggested that the binding contributiono ft he flavone scaffold was strongert han that of the glycosidic moiety.T he glucuronic moiety of baicalin is most likely accommodated between a-helix 1a nd bstrands5 and 6, as residues in these secondary structure elements were selectively affected by baicalin. In contrast, the sugar moiety of quercetin-3-b-glucoside is probably located on the opposite site of the protein, which induces significant shifts on Gly65 and residues on a-helix 2 ( Figure 7c) . Overall, the screening of plant extracts from traditional Chinese medicine allowed us to identify af lavonoids caffold that is able to bind VEGF in the VEGFR binding interface.
Discussion
The term "druggability" is used to describe ab iological target that is known to bind with high affinity to al ow molecular weightd rug. [5] Many proteins, including several relatedt o cancer,a re considered as "undruggable" targets. [76] The only VEGF ligands that have found their way into clinical practice are monoclonal antibodies [34] [35] [36] and, more recently, aptamers. [38] In the present study,w es ummarized several years of work of many members of our research group, and also of several collaborators, in an effortt oe xplore the feasibility of at herapeutic strategy based on blocking the VEGFR interaction by using ligands-other than biologics-able to bind VEGF specifically in the region of interaction with its receptor. Herein, we explored aw ide variety of approaches, including NMR spectroscopy based fragment screening, screening of peptide libraries, and activity screening of plant extracts.T his extensive work providedaclear picture. First, it was difficult to identify high-affinity ligands by using these approaches. Second, the only ligands( weak) that bind to the VEGF surface patch involved in the interaction with the receptora re conformationally restrained cyclic peptides and medium-sized natural products.F inally,a ll the small molecular weighto rganic fragmentsa ble to bind VEGF interactw ith the protein in patches other than the therapeutically relevant one.
This behavior,i np articulart he difficulties encountered to identify smallo rganic fragments targeting the VEGF interacting surface, could be related to the topological and chemicalf ea- www.chemmedchem.org tures of the protein-protein interface. The VEGF-VEGFR-1 binding interface is flat, mainly hydrophobic, and rather large (> 800 2 per receptor unit), [13] which thereby suggestst hat targeting this interaction may be especiallyc hallenging. However, ac ompound interacting with the VEGF binding site in the VEGFR D2 domain and inhibiting complex formationw as recently described. [39] This observation thus indicatest hat this PPI may be amenable to disruption by synthetic compounds. SeveralV EGF segments distant in sequence generateadiscontinuousb inding epitope that contributes to receptor binding. The binding determinants of VEGF for VEGFRa re localized on the N-terminal a-helix1 (residues 16-27), the loop connecting b3t ob4( residues 61-66), and strand b7( residues 103-106) of one VEGF monomer as well as strand b2( residues 46-48) and strands b5a nd b6, and the turn connecting them (residues 79-91).
Protein-protein interfaces could be structurally classified as domain-domain or peptide-domain interactions. [4] In domaindomain PPIs, two globular protein domains are involved in the interface, whereas in peptide-mediated PPIs ac ontinuous polypeptides egment binds to ag lobular domain. Thes ize and shape of the contact area differ considerably between the two interaction types. Peptide-mediated interfaces have relatively small contact areas with hot spot residues in closep roximity. In addition, members of this class tend to contain defined pockets at the interface that may act as anchors of interacting residues.T hese structural features make peptide-mediated interactions more suited for inhibitors than the larger and flatter domain-domain interfaces.
An increasing collection of PPI inhibitors has been described. [8] Representative examples of successfully targeted PPI interactions include, among others, those of the p53 activation domain with MDM2, [77] Bcl-xL proteins with BH3 peptides, [78] and cytokinei nterleukin-2 IL2 with its receptor IL2Ra. [79] More recently,o ur research group reported as eries of photoswitchable inhibitors of clathrin-mediated endocytosis able to disrupt the b-arrestin-b-adaptin 2i nteraction. [80, 81] Most targeted PPIs are either peptide-domain interactions or af raction of domain-domain PPIs that contain ac ontinuous dominant peptide at the interaction interface that contributes most of the binding energy.Int he latter case, inhibitors often target the interface region in which the dominant peptide interacts.
The reasons why targetingV EGF has provent ob ee xtremely challenging are probablycorrelated with the absence of desirable druggable features in VEGF.T he VEGF-VEGFR interaction is atypical domain-domain interaction. VEGF contains arelatively flat and extended interface with hot spots distributed over al arge area. The distance between the Ca of Leu66 and Met18 is~20 . Using several computational techniques, we predicted the lack of preformed or transient cavities or clefts with potential capacity to bind small molecules with reasonable affinity in the receptor binding surface of VEGF.
The presence of large exposed hydrophobic surface patches is one of the signatures of domain-domain PPIs. In this context, our results suggest that to disruptd omain-domain PPIs ligands would need to expose hydrophobic surfaces that are over am inimal threshold. This requirement translates,o nt he one hand, into the need for am inimum molecular weight. On the other hand, conformational constraints are required to prevent these relativelyl arge hydrophobic molecules to adopt energetically favored folded conformations that would shield the hydrophobic functional groupsf rom the water.I no ther words, it would be necessary to force the hydrophobic parts of the molecule to remaine xposed at the surface, which would thus facilitatei nteraction with the hydrophobic patch at the protein surface. Our analysisc ouldb ea pplicable to other targets of this nature and may help in the design of inhibitors and/or screening strategies of many therapeutically relevant domaindomain PPIs.
Experimental Section
Chemistry
Protein production:V EGF 11À109 (VEGF) was expressed, purified, and refolded as described in detail elsewhere. [53] Large-scale expression was performed on a1 0L scale with aB iostat Bf ermentor (Sartorius). In this case, protein expression was induced once the culture reached an optical density of 1.2 at 600 nm (OD 600 ), and cells were harvested at an OD 600 of~6.0. During the fermentation, oxygen was supplemented into gas flow and the pH was kept constant at 7.0.
Peptide synthesis:Astandard solid-phase Fmoc/tBu peptide synthesis protocol was followed. Dipeptide libraries were supplied by Dr.F .Y raola from the Combinatorial Chemistry Unit at the Barcelona Science Park. These libraries were produced by solid-phase synthesis and were purified by HPLC to ap urity 95 %o rh igher.F or storage purposes, compounds were weighed and dissolved in [D 6 ]DMSO at ac oncentration of 100 mm.
For the synthesis of symmetric cyclic hexapeptide &d-Pro-Trp-Glud-Pro-Trp-Glu&, 2-chlorotrityl resin (CTC resin, 250 mg, 1.6 mmol g À1 )w as placed in a2 0mLp olypropylene syringe fitted with ap olyethylene filter disc. The resin was then washed with CH 2 Cl 2 (5 30s)a nd as olution of Fmoc-l-Trp(Boc)-OH (184.3 mg, 0.7 equiv) and N,N-diisopropylethylamine (DIEA;3 66 mL, 10 equiv) in CH 2 Cl 2 was then added;t he mixture was then stirred for 1h at room temperature. The remaining active sites were capped with the addition of MeOH (400 mL), and the mixture was stirred for an additional 10 min at room temperature. The Fmoc-l-Trp(Boc)-O-CTC resin was subjected to the following washes:C H 2 Cl 2 (5 30s), DMF (5 30s), and 20 %p iperidine in DMF (1 1 min, 25min, 1 10 min). Elongation of the peptide was achieved by the sequential addition of Fmoc-AA-OH (3 equiv) with 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronoium hexafluorphosphate (HATU, 3equiv) and DIEA (6 equiv) as coupling reagents in DMF.T he coupling reaction was stirred for 30 min, and before filtration the corresponding colorimetric test (ninhydrin test for primary amines and chloranil test for secondary amines) was done to qualitative assess if coupling reactions were completed. Removal of the Fmoc group was performed with 20 %p iperidine in DMF (1 1 min, 2 10 min, 110 min). The H-Glu(OtBu)-d-Pro-Trp(Boc)-Glu(OtBu)-dPro-Trp(Boc)-O-CTC peptide resin was treated with 1% trifluoroacetic acid (TFA) in CH 2 Cl 2 (5 30s)t oc leave the peptide from the resin. The filtrates were collected over H 2 O( 60 mL per gram of resin). CH 2 Cl 2 was removed under an atmosphere of nitrogen and water was removed by lyophilization. The linear peptide was subjected to head-to-tail cyclization in solution by using (7-azabenzotriazol-1-yloxy)tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) and DIEA as coupling reagents in am ixture of CH 2 Cl 2 /DMF (98:2) at high dilution (5 mm)f or 16 ha tr oom temperature. The cyclic peptide was treated with TFA/H 2 O/triisopropylsilane (TIS) (95:2.5:2.5, v/v/v)f or 2h at room temperature to remove all protecting groups. Solvent was removed under an atmosphere of ni- Plant extracts from traditional Chinese medicine:Plants were obtained from Herbasin (Shenyang, China). Dried plant material (30 g) was extracted with H 2 O( 400 mL) at reflux for 5h by means of aS oxhlet apparatus. The volume of the aqueous extracts was reduced by evaporation under vacuum, and the extract was then freeze dried. Finally, [ D 6 ]DMSO stocks were prepared at a200 mg mL À1 concentration.
NMR spectroscopy
STD and WaterLOGSY experiments were conducted over ar ange of temperatures (37, 25, or 5 8C) with Bruker Digital Avance6 00 MHz and Varian Inova 500 MHz spectrometers. Samples contained 10 mm VEGF and 0.5 or 1mm of assayed compound(s) in 25 mm sodium phosphate (pH 7.0), 50 mm NaCl, and 90 %D 2 O. On-resonance irradiation was performed on the water signal for WaterLOG-SY experiments and on the aliphatic protein region for STD experiments. The total saturation time was 2-2.5 s, and water suppression was achieved with awatergate module.
In the screening experiments, fragments showing STD signals with "normal" or "strong" intensities for more than 30 %o ft heir protons were classified as potential good binders. C HSQC experiments were combined as previously described. [82] For ligands interacting in the receptor-binding site of VEGF,t wo equal and independent binding sites were assumed. [82] All 19 FNMR spectra were acquired with aB ruker spectrometer operating at 700 MHz and equipped with ad ual fluorine-proton SEF probehead and ar obotic arm BACS120. The CF 3 and CF cocktail samples for the 19 FNMR screening were prepared at 20 and 50 mm, respectively,b yd iluting premixed cocktail stocks (10 mm each of the eight compounds in each stock) in [D 6 ]DMSO in af inal volume of 550 mLo fb uffer A.
Two
19
FNMR spectra for each cocktail sample were recorded:aregular 1D and a1Dc ontaining aC PMG T 2 filter of 200/400 ms (for CF/CF 3 ), before and after the addition of 2 mm VEGF.S pectra were recorded with a20Hzsample spinning using 128 scans, acquisition and recovery times of 1.2 sa nd 2.5 s, respectively,i n8 .5-9.5 min per spectrum. Table 3 . Characterization of mRNA display-derivedpeptides. www.chemmedchem.org
